# Ipamorelin Research: The Growth-Hormone-Axis Studies, Charted

> Ipamorelin research, read straight: the 1998 selectivity characterization, the ~2-hour human half-life, the failed Phase 2 ileus trial, and the class-level safety data — each pinned to its study.

From the 1998 selectivity characterization to the 2024 ferret cachexia study — every quantitative claim pinned to the study that measured it.

## The short version

Ipamorelin research is deep on mechanism and thin on people. The founding study proved the thing that makes it interesting — it releases growth hormone without raising stress hormones [1]. A handful of rodent studies measured what that growth-hormone pulse does to bone and body weight [4][10]. One small human study mapped how the drug clears the body [2]. And one human efficacy trial — the only one — tested whether it speeds bowel recovery after surgery, and it failed [3].

Everything else on this page is context: the receptor biology, the gut connection, the CJC-1295 pairing rationale, and the class-level cardiac signal that frames the safety unknowns [6]. Read the bright points (the selectivity, the half-life) as confirmed, and the faint ones (anti-aging, fat loss, the combination) as unproven. Below, each major finding gets its own heading.

## The founding finding: selectivity

Ipamorelin earned its name as the first highly selective growth hormone secretagogue. In primary rat pituitary cells, anaesthetised rats, and conscious swine, it released growth hormone potently — a swine ED50 of 2.3 ± 0.03 nmol/kg, comparable to GHRP-6 — yet did not raise ACTH or cortisol above the level seen with GHRH, even at doses more than 200-fold above its growth-hormone ED50 [1]. That clean separation between growth-hormone release and adrenal stimulation is the property every later use trades on. The characterization was acute, not chronic — it measured single-pulse pharmacology, not what happens over months [1].

## How it works: the ghrelin receptor

Ipamorelin is a ghrelin mimetic. It activates GHS-R1a — the growth hormone secretagogue receptor type 1a, which is the same receptor the natural hunger hormone ghrelin uses — on the pituitary's growth-hormone cells, and that triggers a discrete pulse of growth hormone [1]. There is also a peripheral arm: radiolabeled tracer work showed that GHRPs and the ipamorelin-derived NN703 accumulate in the gastric mucosa (where ghrelin is made), and gastric resection cut GHRP-6-induced growth-hormone release by 60–70% but left GHRH-induced release intact — suggesting GHRPs partly act by triggering the body's own ghrelin [11]. That gut-pituitary link is also why the class stimulates appetite and gastric motility [12], and the same prokinetic biology is what put ghrelin-receptor agonists into postoperative-ileus development in the first place — a related agonist, TZP-101, reversed surgery- and opioid-induced gut-transit delay in a rat ileus model [13].

## Human data

Human evidence is limited and largely negative. The one clean human dataset is pharmacokinetic: in healthy male volunteers (n=8 per dose level; five 15-minute IV infusions of 4.21–140.45 nmol/kg), ipamorelin showed dose-proportional kinetics with a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg; the growth-hormone response peaked near 40 minutes (0.67 h) as a single discrete pulse [2].

The one human efficacy trial is the defining anchor — and it is negative. In a Phase 2 RCT for postoperative ileus (NCT00672074; 114 adults undergoing bowel resection given 0.03 mg/kg IV twice daily for up to 7 days), ipamorelin missed its primary endpoint: median time to first tolerated meal was 25.3 hours versus 32.6 hours on placebo (p=0.15) [3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific safety signal in that short window, but also no demonstrated efficacy [3].

## The rodent skeletal and metabolic studies

The bone data are the most-cited efficacy signal. Subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily for 15 days) dose-dependently raised the longitudinal bone-growth rate of adult female Sprague-Dawley rats — from 42 µm/day on vehicle to 44, 50, and 52 µm/day respectively — with no change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. That last detail matters: the effect tracked the growth-hormone pulse without a measurable rise in systemic IGF-1, pointing to a partly local, pulse-driven skeletal action [4].

The most recent in-vivo study is a 2024 ferret cachexia model: intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48–72 h), but had no anti-emetic effect on either acute or delayed emesis — in contrast to centrally administered anamorelin, which cut acute emesis by 60% [5]. The weight-loss protection came through a peripheral mechanism.

## The class-level cardiotoxicity signal

This is the study that keeps an honest ipamorelin page from overpromising. An integrated preclinical safety-pharmacology study of GSK894281 — a *different* GHS-R1a agonist in the same receptor class — found dose-dependent myocardial degeneration and necrosis in rats after 28 days of oral dosing (0.3–60 mg/kg/day), detectable by histopathology and electron microscopy and accompanied by elevated serum heart-type fatty-acid-binding protein (FABP3) at the highest doses, while serum cardiac troponin was not elevated [6]. Ipamorelin was not the tested compound, and no equivalent long-duration cardiovascular study of ipamorelin exists — which is precisely the point: the receptor class carries a chronic-dosing cardiac hazard that ipamorelin's own record has never addressed [6].

## Ipamorelin cjc-1295

The pairing of ipamorelin with cjc-1295 rests on complementary mechanisms, not on a trial of the combination. CJC-1295 is a long-acting GHRH analog; a serum-protein-profile analysis characterized its activation of the GH/IGF-1 axis, reinforcing the durable IGF-1 elevation that motivates combining a GHRH analog with a short-acting GHRP such as ipamorelin [7]. The rationale is that the two hit different receptors — GHRH-receptor versus ghrelin-receptor — so their growth-hormone-releasing effects can add together. A 2026 orthopaedic narrative review reported that the CJC-1295 + ipamorelin combination improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss mouse model [14]. That is preclinical and narrative; no controlled human trial of the combination exists for any outcome.

## What is cjc-1295 ipamorelin

On *what is cjc 1295 ipamorelin*: it is a two-peptide pairing, not a single drug. Ipamorelin is the short-acting ghrelin-receptor agonist that fires a growth-hormone pulse [1]; CJC-1295 is the long-acting GHRH analog that sustains the underlying GH/IGF-1 axis tone [7]. Combined, they are meant to produce a larger, more durable growth-hormone signal than either alone. Neither component is approved, and the combination's evidence is single-agent pharmacology stitched together — the pair itself has not been tested in a controlled trial.

## Does cjc-1295 ipamorelin work

Asking *does cjc-1295 ipamorelin work* requires splitting 'work.' Each peptide does what its pharmacology says: ipamorelin releases a growth-hormone pulse [1], and CJC-1295 raises and sustains IGF-1 [7]. Whether the combination delivers the anti-aging, fat-loss, or muscle outcomes it is marketed for has not been shown in any controlled human trial. The closest evidence is a preclinical muscle-tension result in a mouse model from a 2026 review [14] — promising in a dish, unproven in people. The combination 'works' pharmacologically and is unproven clinically.

## Ipamorelin vs sermorelin

On *ipamorelin vs sermorelin*: these sit in different families. Ipamorelin is a GHRP — a ghrelin-receptor agonist [1]. Sermorelin is a GHRH analog, acting on the GHRH receptor; a clinical review framed sermorelin as a GHRH-analog approach to restoring growth-hormone secretion in adult-onset growth-hormone insufficiency [8]. Practically, that means the two release growth hormone through different receptors and are often discussed as complementary rather than interchangeable. Sermorelin has a longer clinical-use history in the GHRH-analog class; ipamorelin's defining edge is its hormonal selectivity [1].

## Ipamorelin vs tesamorelin

On *ipamorelin vs tesamorelin*: tesamorelin is also a GHRH analog, not a GHRP, so like sermorelin it works through the GHRH receptor rather than the ghrelin receptor ipamorelin uses [1][8]. The functional contrast is mechanism-of-release plus evidence base: tesamorelin carries a defined approved clinical use in its own right, whereas ipamorelin has no approved indication and a single failed efficacy trial [3]. This site does not compare them as products; the distinction here is purely pharmacological class and the state of each compound's published record.

---

A star-chart reading of the ipamorelin record — the bright confirmed points (the 1998 selectivity, the ~2-hour human half-life) charted apart from the faint speculative ones, and the regulatory status read straight from the register; no clinic behind the atlas and nothing here dosed, compounded, prescribed, or sold.